Submit Deal

INVETX

Summary

Invetx is a biotechnology company, a division of Dechra Pharmaceuticals, focused on developing novel, protein-based therapeutics for dogs and cats, aiming to transform veterinary care for chronic conditions like pain, allergy, and cancer.

Deals Overview

Total Deals3

Valued Deals3

Total Value£ 461 M

Avg. Deal Size£ 154 M

Market Context

Senior Management

Juergen Horn
CEO
Jeff Troderman
CFO

Sort

24 Feb 2020|United States|Pharmaceuticals

Target: INVETX

Bidder: ANTERRA CAPITAL

4 Service Providers

3 Target | 1 Bidder

5 Dealmakers

4 Target | 1 Bidder

£ 11 M

Value

10 May 2022|United States|Pharmaceuticals

Target: INVETX

Bidder: F-PRIME CAPITAL

10 Service Providers

3 Target | 7 Bidder

13 Dealmakers

6 Target | 7 Bidder

£ 49 M

Value

18 Jul 2024|United States|Pharmaceuticals

Target: INVETX

Bidder: EQT PARTNERS

5 Service Providers

4 Target | 1 Bidder

7 Dealmakers

5 Target | 2 Bidder

£ 399 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy